» Articles » PMID: 9203654

Heterotypic Protection Following Oral Immunization with Live Heterologous Rotaviruses in a Mouse Model

Overview
Journal J Infect Dis
Date 1997 Feb 1
PMID 9203654
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

A Jennerian approach using live animal viruses to immunize humans is the current lead strategy for developing rotavirus vaccines. This strategy has been modified by incorporating human rotavirus VP7 genes into vaccine strains to induce serotype-specific neutralizing antibodies to human strains. However, the role of homotypic versus heterotypic immunity in protection is unclear. To investigate the importance of serotype-specific immunity in a mouse model, mice were immunized with rhesus rotavirus (RRV: G3, P5[3]), RRV-based modified Jennerian vaccine strains DxRRV (G1, P5[3]), DS1xRRV (G2, P5[3]), or ST3xRRV (G4, P5[3]), or bovine rotavirus NCDV (G6, P6[1]) and challenged with murine rotavirus ECw (G3, P[16]). Mice immunized with modified Jennerian vaccines exhibited complete to near-complete protection from challenge. NCDV-immunized mice also showed partial protection. The protection was correlated with fecal IgA levels to VP6, not serum IgG responses. Modified Jennerian vaccines induce both heterotypic and homotypic immunity in mice.

Citing Articles

Viral gastroenteritis: Causes, pathophysiology, immunology, treatment, and epidemiology.

Perspect Med Virol. 2020; 9:1-8.

PMID: 32336841 PMC: 7172247. DOI: 10.1016/S0168-7069(03)09001-3.


Profiling of rotavirus 3'UTR-binding proteins reveals the ATP synthase subunit ATP5B as a host factor that supports late-stage virus replication.

Ren L, Ding S, Song Y, Li B, Ramanathan M, Co J J Biol Chem. 2019; 294(15):5993-6006.

PMID: 30770472 PMC: 6463704. DOI: 10.1074/jbc.RA118.006004.


Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges.

Angel J, Steele A, Franco M Hum Vaccin Immunother. 2014; 10(12):3659-71.

PMID: 25483685 PMC: 4514048. DOI: 10.4161/hv.34361.


Plasmacytoid dendritic cells promote rotavirus-induced human and murine B cell responses.

Deal E, Lahl K, Narvaez C, Butcher E, Greenberg H J Clin Invest. 2013; 123(6):2464-74.

PMID: 23635775 PMC: 3668833. DOI: 10.1172/JCI60945.


An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic....

Azevedo M, Gonzalez A, Yuan L, Jeong K, Iosef C, Nguyen T Clin Vaccine Immunol. 2010; 17(3):420-8.

PMID: 20107005 PMC: 2837955. DOI: 10.1128/CVI.00395-09.